Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease

Cytomegalovirus-specific T-cell Reconstitution following Letermovir Prophylaxis after Hematopoietic Cell Transplantation

(2021) Danniel Zamora et al.   BLOOD

Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis

(2021) Kaiwen Chen et al.   Transplant Infectious Disease

Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program

(2020) Christine Robin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

(2020) Hermann Einsele et al.   BLOOD

Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant

(2020) Joyce J. Johnsrud et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study

(2020) Jan Styczyński et al.   BONE MARROW TRANSPLANTATION

Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality

(2020) Yu Akahoshi et al.   CLINICAL INFECTIOUS DISEASES

Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation

(2019) Jose Paulo Martins et al.   SCIENCE

Direct adjusted survival and cumulative incidence curves for observational studies

(2019) Zhen-Huan Hu et al.   BONE MARROW TRANSPLANTATION

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)

(2019) Per Ljungman et al.   LANCET INFECTIOUS DISEASES

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation

(2019) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

(2019) Christopher Andrew Lamb et al.   GUT

Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials

(2018) Roy F Chemaly et al.   CLINICAL INFECTIOUS DISEASES

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

(2017) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

(2016) P. Teira et al.   BLOOD

How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients

(2016) F. El Chaer et al.   BLOOD

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

(2016) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

(2016) Margaret L Green et al.   Lancet Haematology

Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation

(2015) Nada Hamad et al.   AMERICAN JOURNAL OF HEMATOLOGY

Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease

(2015) Divaya Bhutani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group

(2015) Katsuto Takenaka et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice

(2015) M. E. Wikstrom et al.   BLOOD

CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire

(2015) Yvonne Suessmuth et al.   BLOOD

Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)

(2015) Yoshiko Atsuta   INTERNATIONAL JOURNAL OF HEMATOLOGY

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

(2014) P. Armand et al.   BLOOD

Donor Cytomegalovirus Status Influences the Outcome of Allogeneic Stem Cell Transplant: A Study by the European Group for Blood and Marrow Transplantation

(2014) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Clinical Factors Predicting the Response of Acute Graft-versus-Host Disease to Corticosteroid Therapy: An Analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation

(2013) Makoto Murata et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy

(2012) Byung-Sik Cho et al.   ANNALS OF HEMATOLOGY

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

(2012) Margaret L. Green et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

(2011) Per Ljungman et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

(2011) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models

(2010) Xu Zhang et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research

(2009) Sergio Giralt et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

How we treat cytomegalovirus in hematopoietic cell transplant recipients

(2009) M. Boeckh et al.   BLOOD

A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT

(2009) Y Kanda et al.   BONE MARROW TRANSPLANTATION

Diagnostic Performance of the Cytomegalovirus (CMV) Antigenemia Assay in Patients with CMV Gastrointestinal Disease

(2009) Eun‐Young Jang et al.   CLINICAL INFECTIOUS DISEASES

Graft-versus-host disease

(2009) James LM Ferrara et al.   LANCET

Current and novel therapies in acute GVHD

(2008) Vincent T. Ho et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY